Chemical Diversity: Difference between revisions
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Userspace draft|source=ArticleWizard|date=March 2011}} |
{{Userspace draft|source=ArticleWizard|date=March 2011}} |
||
'''Chemical Diversity (ChemDiv)''' is a fully integrated CRO headquartered in San Diego, CA, with subsidiaries in Russia and Ukraine. It provides pharmaceutical and biotech companies integrated discovery and development solutions for their R&D programs. ChemDiv's services cover a range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market. |
'''Chemical Diversity (ChemDiv)''' is a fully integrated [[Contract research organization/CRO]] headquartered in [[San Diego]], [[California/CA]], with subsidiaries in [[Russia]] and [[Ukraine]]. It provides pharmaceutical and biotech companies integrated discovery and development solutions for their [[R&D]] programs. ChemDiv's services cover a range of disciplines needed to bring a new project in [[CNS]], [[oncology]], [[inflammation]], [[metabolism/metabolic]], [[Infectious disease/infectious]] and other diseases from identification of a [[biological target]] ([[protein expression]], [[assay]] development etc.) to clinical drug candidates ([[ADME]]/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market. |
||
ChemDiv started in 1990 as a chemistry provider and has moved to a full service CRO since. Among its partners are Eli Lilly<ref>ChemDiv-Lilly Collaboration Expanded to Include New Discovery Program, Fierce Biotech, August 20, 2009, [http://www.fiercebiotech.com/press-releases/chemdiv-lilly-collaboration-expanded-include-new-discovery-program]</ref>, Novartis, Dendreon, Merck KGaA, Solvay |
ChemDiv started in 1990 as a chemistry provider and has moved to a full service [[Contract research organization/CRO]] since. Among its partners are [[Eli Lilly]]<ref>ChemDiv-Lilly Collaboration Expanded to Include New Discovery Program, Fierce Biotech, August 20, 2009, [http://www.fiercebiotech.com/press-releases/chemdiv-lilly-collaboration-expanded-include-new-discovery-program]</ref>, [[Novartis]], [[Dendreon]], [[Merck KGaA]], [[Solvay Pharmaceutical]], [[Bayer]], etc. |
||
Revision as of 20:01, 2 March 2011
Chemical Diversity (ChemDiv) is a fully integrated Contract research organization/CRO headquartered in San Diego, California/CA, with subsidiaries in Russia and Ukraine. It provides pharmaceutical and biotech companies integrated discovery and development solutions for their R&D programs. ChemDiv's services cover a range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolism/metabolic, Infectious disease/infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market.
ChemDiv started in 1990 as a chemistry provider and has moved to a full service Contract research organization/CRO since. Among its partners are Eli Lilly[1], Novartis, Dendreon, Merck KGaA, Solvay Pharmaceutical, Bayer, etc.